Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001654954-25-011797
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 1.01
Chunk 2
---
 Management, LLC, a limited liability company (“ Arca”), pursuant to which the Company engaged Arca to provide asset management services in accordance with the investment strategy and investment objectives, policies, guidelines and restrictions as agreed to from time to time by the Company and Arca.

The assets subject to the Investment Management Agreement will initially consist of approximately $3.5 million of proceeds from the Offering. Arca will have discretion to manage funds allocated to the Company’s DAT strategy, focusing on decentralized finance, including, without limitation, by purchasing $HYPE, the native digital asset of the Hyperliquid network, directly or indirectly through the use of derivative instruments.

Pursuant to the Investment Management Agreement, the Company will pay Arca a fee ranging from 1.25% to 1.75% of assets under management, based on the amount of such assets under management (“ AUM”), per annum and payable monthly. Additionally, the Company will pay Arca a performance fee ranging from 10% to 15% of the net total return of the underlying assets, based on the amount of such assets under management. In connection with the closing of the Offering and pursuant to the Investment Management Agreement, the Company issued to Arca warrants to purchase an aggregate of 400,000 shares of Common Stock (the “ Advisory Warrants”). Advisory Warrants in respect of 100,000 shares are exercisable immediately for an exercise price equal to $6.95, or 110% of the exercise price of the Common Warrants. Advisory Warrants in respect of 300,000 shares become exercisable in the event that AUM exceeds certain thresholds within six or nine months following the closing, at exercise prices ranging from $6.95 to $7.50. The Advisory Warrants were offered and sold in reliance upon the exemption from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, and applicable state securities laws.

The Investment Management Agreement may be terminated by either the Company or Arca upon not more than sixty (60) days’ but not less than thirty (30) days’ written notice to the other party.

The foregoing descriptions of the Investment Management Agreement and the Advisory Warrants do not purport to be complete and are qualified in their entirety by the full text of such documents, which are filed herewith as Exhibits 10.3 and 4.4, respectively.

Custody

The Company plans to hold substantially all